BMEA
Biomea Fusion, Inc. NASDAQ Listed Apr 16, 2021$1.18
-1.67%
vs $1.20
Mkt Cap $61.6M
52w Low $0.96
13.0% of range
52w High $2.67
50d MA $1.50
200d MA $1.46
P/E (TTM)
—
EV/EBITDA
—
P/B
2.1x
Debt/Equity
0.1x
ROE
-209.1%
P/FCF
-0.9x
RSI (14)
33.30
ATR (14)
$0.10
Beta
-0.27
50d MA
$1.50
200d MA
$1.46
Avg Volume
1.1M
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
900 Middlefield Road · Redwood City, CA 94063 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | -0.25 | -0.64 | -156.0% | 1.13 | +0.9% | +8.0% | +12.3% | -3.6% | +0.0% | +15.9% | — |
| Nov 4, 2025 | AMC | -0.26 | -0.27 | -3.8% | 1.26 | -0.8% | +6.3% | -3.0% | +5.4% | +0.0% | +2.2% | — |
| Aug 5, 2025 | AMC | -0.59 | -0.51 | +13.6% | 1.58 | +1.9% | +0.6% | +2.5% | -5.5% | -0.6% | +7.8% | — |
| May 5, 2025 | AMC | -0.84 | -0.80 | +4.8% | 2.00 | -4.0% | -16.5% | +1.8% | +2.9% | -6.9% | +8.6% | — |
| Mar 31, 2025 | AMC | -1.00 | -0.81 | +19.0% | 2.13 | +5.2% | -6.6% | +8.5% | -9.7% | +8.7% | -5.2% | — |
| Oct 29, 2024 | AMC | -1.05 | -0.91 | +13.3% | 12.06 | +1.0% | -14.3% | -9.4% | -3.5% | -2.2% | +0.8% | — |
| Jul 31, 2024 | AMC | -1.03 | -1.03 | +0.0% | 5.57 | +6.6% | +3.2% | -0.9% | -0.5% | +7.6% | -5.4% | — |
| May 2, 2024 | AMC | -1.02 | -1.09 | -6.9% | 11.93 | +7.5% | +3.5% | -0.7% | -2.1% | -7.8% | +3.3% | — |
| Apr 1, 2024 | AMC | -0.85 | -0.98 | -15.3% | 15.30 | -9.9% | -16.3% | +9.1% | -9.7% | +1.0% | -1.7% | — |
| Oct 30, 2023 | AMC | -0.83 | -0.80 | +3.6% | 11.06 | -7.3% | -7.6% | +2.3% | -3.7% | +0.3% | -8.2% | — |
| Jul 31, 2023 | AMC | -0.86 | -0.70 | +18.6% | 22.25 | +0.3% | -6.7% | -7.5% | -1.1% | +1.7% | -5.3% | — |
| May 2, 2023 | AMC | -0.80 | -0.98 | -22.5% | 29.00 | +3.1% | +5.8% | +4.4% | +1.6% | +2.6% | +1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | D. Boral Capital | Maintains | Buy → Buy | — | $1.73 | $1.72 | -0.6% | -11.6% | -4.6% | -6.8% | +0.7% | +8.0% |
| Apr 8 | D. Boral Capital | Maintains | Buy → Buy | — | $1.90 | $1.90 | +0.0% | -7.4% | +5.1% | +1.1% | +0.5% | +3.7% |
| Mar 27 | Citigroup | Maintains | Buy → Buy | — | $1.37 | $1.36 | -0.7% | -3.6% | +0.0% | +15.9% | -2.6% | +3.4% |
| Mar 25 | D. Boral Capital | Maintains | Buy → Buy | — | $1.13 | $1.14 | +0.9% | +8.0% | +12.3% | -3.6% | +0.0% | +15.9% |
| Jan 13 | D. Boral Capital | Maintains | Buy → Buy | — | $1.46 | $1.52 | +4.1% | +4.1% | +6.6% | -13.6% | +0.7% | -2.1% |
| Nov 10 | Citigroup | Maintains | Buy → Buy | — | $1.37 | $1.40 | +2.2% | +0.0% | +2.2% | -2.1% | -5.8% | -0.8% |
| Nov 5 | D. Boral Capital | Maintains | Buy → Buy | — | $1.26 | $1.25 | -0.8% | +6.3% | -3.0% | +5.4% | +0.0% | +2.2% |
| Oct 27 | D. Boral Capital | Maintains | Buy → Buy | — | $1.46 | $1.48 | +1.4% | -2.7% | -2.8% | -0.7% | -2.9% | +2.3% |
| Oct 7 | D. Boral Capital | Maintains | Buy → Buy | — | $2.67 | $1.98 | -25.8% | -30.7% | -9.2% | +6.5% | -6.1% | -1.8% |
| Oct 3 | D. Boral Capital | Maintains | Buy → Buy | — | $2.13 | $2.15 | +0.9% | +0.9% | +24.2% | -30.7% | -9.2% | +6.5% |
| Aug 11 | Citigroup | Maintains | Buy → Buy | — | $1.54 | $1.55 | +0.6% | -0.6% | +7.8% | +4.2% | -1.7% | +2.4% |
| Aug 6 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $1.58 | $1.61 | +1.9% | +0.6% | +2.5% | -5.5% | -0.6% | +7.8% |
| Aug 6 | D. Boral Capital | Maintains | Buy → Buy | — | $1.58 | $1.61 | +1.9% | +0.6% | +2.5% | -5.5% | -0.6% | +7.8% |
| Jul 21 | D. Boral Capital | Maintains | Buy → Buy | — | $1.85 | $1.89 | +2.2% | -1.1% | -0.5% | +1.6% | -2.2% | +1.1% |
| Jul 16 | Citigroup | Maintains | Buy → Buy | — | $1.78 | $1.85 | +3.9% | +7.3% | -1.6% | -1.6% | -1.1% | -0.5% |
| Jun 24 | D. Boral Capital | Maintains | Buy → Buy | — | $1.69 | $1.77 | +4.7% | +11.2% | +3.2% | +2.6% | -9.0% | -0.6% |
| Jun 18 | D. Boral Capital | Maintains | Buy → Buy | — | $2.90 | $2.06 | -29.0% | -34.1% | -5.2% | -6.6% | +11.2% | +3.2% |
| Jun 13 | D. Boral Capital | Maintains | Buy → Buy | — | $2.61 | $2.57 | -1.5% | -9.6% | +11.4% | +10.3% | -34.1% | -5.2% |
| May 15 | D. Boral Capital | Maintains | Buy → Buy | — | $1.46 | $1.46 | +0.0% | -2.1% | +6.3% | -0.7% | +4.0% | -7.6% |
| May 6 | D. Boral Capital | Maintains | Buy → Buy | — | $2.00 | $1.92 | -4.0% | -16.5% | +1.8% | +2.9% | -6.9% | +8.6% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.00 | $1.92 | -4.0% | -16.5% | +1.8% | +2.9% | -6.9% | +8.6% |
| Apr 2 | Barclays | Maintains | Equal Weight → Equal Weight | — | $1.99 | $1.94 | -2.5% | +8.5% | -9.7% | +8.7% | -5.2% | -14.9% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.13 | $2.24 | +5.2% | -6.6% | +8.5% | -9.7% | +8.7% | -5.2% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.30 | $2.25 | -2.2% | -7.4% | -6.6% | +8.5% | -9.7% | +8.7% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.79 | $2.82 | +1.1% | -3.6% | -6.3% | -1.2% | -7.6% | -7.4% |
| Mar 24 | D. Boral Capital | Maintains | Buy → Buy | — | $2.87 | $3.00 | +4.5% | -2.8% | -3.6% | -6.3% | -1.2% | -7.6% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.87 | $3.00 | +4.5% | -2.8% | -3.6% | -6.3% | -1.2% | -7.6% |
| Mar 19 | D. Boral Capital | Maintains | Buy → Buy | — | $2.53 | $2.55 | +0.8% | +7.9% | +1.5% | +3.6% | -2.8% | -3.6% |
| Jan 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.06 | $4.17 | +2.7% | +0.0% | -2.0% | +6.8% | +1.6% | +3.7% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.15 | $4.15 | +0.0% | +0.0% | -2.2% | +0.0% | -2.0% | +6.8% |
| Jan 13 | D. Boral Capital | Maintains | Buy → Buy | — | $3.98 | $3.84 | -3.5% | +4.3% | +0.0% | -2.2% | +0.0% | -2.0% |
| Jan 10 | D. Boral Capital | Maintains | Buy → Buy | — | $4.27 | $4.21 | -1.4% | -6.8% | +4.3% | +0.0% | -2.2% | +0.0% |
| Dec 19 | D. Boral Capital | Maintains | Buy → Buy | — | $3.88 | $4.02 | +3.6% | +5.2% | +3.7% | -4.7% | -0.5% | +1.7% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.64 | $4.62 | -0.4% | -16.4% | +5.2% | +3.7% | -4.7% | -0.5% |
| Dec 17 | D. Boral Capital | Maintains | Buy → Buy | — | $5.85 | $5.21 | -10.9% | -20.7% | -16.4% | +5.2% | +3.7% | -4.7% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.64 | $5.69 | +0.9% | +3.7% | -20.7% | -16.4% | +5.2% | +3.7% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.79 | $5.85 | +1.0% | -0.5% | +6.6% | -5.5% | -2.8% | +3.7% |
| Dec 10 | D. Boral Capital | Maintains | Buy → Buy | — | $5.79 | $5.85 | +1.0% | -0.5% | +6.6% | -5.5% | -2.8% | +3.7% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.28 | $6.28 | +0.0% | +1.6% | +0.9% | +7.6% | -0.6% | +1.9% |
| Nov 19 | D. Boral Capital | Maintains | Buy → Buy | — | $6.43 | $6.45 | +0.3% | -0.2% | -2.2% | +1.6% | +0.9% | +7.6% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.34 | $10.46 | +1.2% | -9.4% | -3.5% | -2.2% | +0.8% | -0.3% |
| Oct 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.34 | $10.46 | +1.2% | -9.4% | -3.5% | -2.2% | +0.8% | -0.3% |
| Oct 31 | EF Hutton | Maintains | Buy → Buy | — | $10.34 | $10.46 | +1.2% | -9.4% | -3.5% | -2.2% | +0.8% | -0.3% |
| Oct 30 | Barclays | Maintains | Equal Weight → Equal Weight | — | $12.06 | $12.18 | +1.0% | -14.3% | -9.4% | -3.5% | -2.2% | +0.8% |
| Oct 30 | EF Hutton | Maintains | Buy → Buy | — | $12.06 | $12.18 | +1.0% | -14.3% | -9.4% | -3.5% | -2.2% | +0.8% |
| Oct 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.24 | $11.25 | +0.1% | +2.0% | -1.4% | +2.2% | +5.1% | +2.1% |
| Oct 22 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $11.24 | $11.25 | +0.1% | +2.0% | -1.4% | +2.2% | +5.1% | +2.1% |
| Sep 27 | Truist | Upgrade | Hold → Buy | — | $9.57 | $11.48 | +20.0% | +3.4% | +2.0% | -5.9% | +6.6% | -0.4% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.57 | $11.48 | +20.0% | +3.4% | +2.0% | -5.9% | +6.6% | -0.4% |
| Sep 27 | Barclays | Maintains | Equal Weight → Equal Weight | — | $9.57 | $11.48 | +20.0% | +3.4% | +2.0% | -5.9% | +6.6% | -0.4% |
No insider trades available.
8-K
Biomea Fusion, Inc. -- 8-K Filing
Jun 11
8-K
Cue Biopharma, Inc. -- 8-K Filing
Jun 2
8-K · 2.02
!! High
Biomea Fusion, Inc. -- 8-K 2.02: Earnings Results
May 11
8-K · 7.01
! Medium
Biomea Fusion, Inc. -- 8-K 7.01: Regulation FD Disclosure
Biomea Fusion furnished investor presentation slides for an upcoming call, signaling management intends to communicate updates on company strategy or performance directly to shareholders.
Apr 28
8-K
Unknown — 8-K Filing
Biomea's lead diabetes drug showed sustained benefits months after short treatment, potentially supporting a valuable therapeutic approach that could drive near-term clinical advancement and investor confidence.
Mar 24
8-K · 7.01
! Medium
Biomea Fusion, Inc. -- 8-K 7.01: Regulation FD Disclosure
Biomea Fusion disclosed a corporate presentation to investors via their website, providing updated company information for stakeholder review.
Feb 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 8,813,359 | $13M | — | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 2,597,300 | $4M | New | Mar 2026 |
| 3 | Aisling Capital Management Lp | 2,048,757 | $3M | — | Mar 2026 |
| 4 | Renaissance Technologies Llc | 1,312,798 | $2M | Added | Mar 2026 |
| 5 | Marshall Wace, Llp | 1,198,551 | $2M | Added | Mar 2026 |
| 6 | Citadel Advisors Llc | 656,817 | $1M | New | Mar 2026 |
| 7 | Susquehanna International Group, Llp | 629,865 | $964K | Added | Mar 2026 |
| 8 | Morgan Stanley | 745,258 | $924K | Reduced | Dec 2025 |
| 9 | Fideuram - Intesa Sanpaolo Private Banking S.p.a. | 557,036 | $852K | Reduced | Mar 2026 |
| 10 | Ubs Group Ag | 515,555 | $789K | Added | Mar 2026 |
| 11 | Two Sigma Investments, Lp | 388,696 | $595K | Reduced | Mar 2026 |
| 12 | Superstring Capital Management Lp | 250,000 | $382K | — | Mar 2026 |
| 13 | Northern Trust Corp | 208,965 | $320K | — | Mar 2026 |
| 14 | Marex Group Plc | 100,000 | $153K | — | Mar 2026 |
| 15 | Griffin Asset Management, Inc. | 58,300 | $89K | — | Mar 2026 |
| 16 | Jane Street Group, Llc | 69,479 | $86K | Reduced | Dec 2025 |
| 17 | Barclays Plc | 51,606 | $79K | Reduced | Mar 2026 |
| 18 | Hrt Financial Lp | 47,852 | $73K | New | Mar 2026 |
| 19 | Quadrature Capital Ltd | 46,162 | $71K | Reduced | Mar 2026 |
| 20 | Adar1 Capital Management, Llc | 43,420 | $66K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 14
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Growth Company Fund | 2,711,793 | $4M | Feb 2026 |
| 2 | Fidelity Growth Company K6 Fund | 918,983 | $1M | Feb 2026 |
| 3 | Fidelity Series Growth Company Fund | 804,702 | $1M | Feb 2026 |
| 4 | Select Biotechnology Portfolio | 452,663 | $620K | Feb 2026 |
| 5 | Fidelity Extended Market Index Fund | 185,149 | $254K | Feb 2026 |
| 6 | iShares Micro-Cap ETF | 161,704 | $247K | Mar 2026 |
| 7 | Fidelity Total Market Index Fund | 109,135 | $150K | Feb 2026 |
| 8 | Ultra-Small Company Market Fund | 84,600 | $129K | Mar 2026 |
| 9 | Federated Hermes MDT Small Cap Core Fund | 96,423 | $108K | Jan 2026 |
| 10 | Fidelity Series Total Market Index Fund | 75,590 | $104K | Feb 2026 |
| 11 | Small Cap Core Fund | 21,888 | $33K | Mar 2026 |
| 12 | Fidelity Nasdaq Composite Index Fund | 18,130 | $25K | Feb 2026 |
| 13 | AST Small-Cap Equity Portfolio | 2,530 | $3K | Dec 2025 |
| 14 | Knights of Columbus U.S. ALL CAP INDEX FUND | 304 | $340 | Jan 2026 |
Valuation
Market Cap
$61.6M
Enterprise Value
$5.8M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.02x
P/B
2.09x
P/S
—
P/FCF
-0.88x
EV/EBITDA
—
Shares Out
52.2M
Financials (TTM)
Revenue
$0
Net Income
-$45.0M
EBITDA
-$46.1M
Free Cash Flow
-$70.4M
Op Cash Flow
-$70.4M
EPS Basic
$-1.18
EPS Diluted
$-0.89
EPS Forward
$-0.94
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$58.6M
Total Liab.
$29.0M
Total Equity
$29.6M
Cash
$55.8M
LT Debt
$0
Book Value/Sh
$0.57
Debt/Equity
0.05x
Current Ratio
5.23
Quick Ratio
5.23
Returns & Growth
ROE
-209.1%
ROA
-105.5%
ROIC
-166.2%
Rev Growth YoY
+0.0%
EPS Growth YoY
+69.2%
Price Returns
2W
-3.5%
1M
+1.5%
3M
+0.7%
6M
+26.6%
12M
-4.2%
Technicals
52W High
$2.67
52W Low
$0.96
50d MA
$1.50
200d MA
$1.46
RSI (14)
33.30
ATR (14)
$0.10
Beta
-0.27
Avg Volume
1.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$20.20
High
$40.00
Low
$10.00
Median
$19.00
Data updated apr 24, 2026 10:09pm
· Source: financialmodelingprep.com